Sina Jasmin Wille

Sina Jasmin Wille

Auto-generated profile, based on publicly available information

Sina Jasmin Wille

Division of Chromatin Networks, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany and Center for Quantitative Analysis of Molecular and Cellular Biosystems (BioQuant), Heidelberg University, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
ARAnne Rademacher
Anne Rademacher
AHAlik Huseynov
Alik Huseynov
MBMichele Bortolomeazzi
Michele Bortolomeazzi
SWSina Jasmin Wille
Sina Jasmin Wille
SSSabrina Schumacher
Sabrina Schumacher
KRKarsten Rippe
Karsten Rippe
Background: Spatial transcriptomics ( ST ) technologies are revolutionizing our understanding of intra-tumor heterogeneity and the tumor microenvironment by revealing single-cell molecular profiles within their spatial tissue context. The rapid evolution of ST methods, each with unique features, presents a challenge in selecting the most appropriate technology for specific research objectives. Here, we compare four imaging-based ST methods – RNAscope HiPlex, Molecular Cartography, MERFISH/Merscope, and Xenium – together with sequencing-based ST (Visium). These technologies were used to study cryosections of medulloblastoma with extensive nodularity (MBEN), a tumor chosen for its distinct microanatomical features. Results: Our analysis reveals that automated imaging-based ST methods are well suited to delineating the intricate MBEN microanatomy, capturing cell-type-specific transcriptome profiles. We devise approaches to compare the sensitivity and specificity of the different methods together with their unique attributes to guide method selection based on the research aim. Furthermore, we demonstrate how reimaging of slides after the ST analysis can markedly improve cell segmentation accuracy and integrate additional transcript and protein readouts to expand the analytical possibilities and depth of insights. Conclusions: This study highlights key distinctions between various ST technologies and provides a set of parameters for evaluating their performance. Our findings aid in the informed choice of ST methods and delineate approaches for enhancing the resolution and breadth of spatial transcriptomic analyses, thereby contributing to advancing ST applications in solid tumor research.

29 July 2025 in Antiviral Research
Verified
Journal Article
Open access
DKDoha Al Krad
Doha Al Krad
KSKim M. Stegmann
Kim M. Stegmann
ADAntje Dickmanns
Antje Dickmanns
PKPriya Kumar
Priya Kumar
CBClaudia Blaurock
Claudia Blaurock
MDMatthias Dobbelstein
Matthias Dobbelstein
Nirmatrelvir, the active compound of the drug Paxlovid, inhibits the Main protease of SARS-CoV-2 (MPro, 3CLPro, NSP5). Its therapeutic application reduces but does not abolish the progression of COVID-19 in humans. Here we report a strong synergy of Nirmatrelvir with inhibitors of the ER chaperone GRP78 (HSPA5, BiP). Combining Nirmatrelvir with the GRP78-antagonizing drug candidate HA15 strongly inhibits the replication of SARS-CoV-2, to a far greater extent than either drug alone, as observed by diminished cytopathic effect, levels of detectable virus RNA, TCID50 titers, and reduced accumulation of the non-structural proteins, as well as Spike and N proteins. The original SARS-CoV-2 strain as well as an Omicron variant were similarly susceptible towards the drug combination. Other GRP78 inhibitors or siRNAs targeting GRP78 also fortified the antiviral effect of Nirmatrelvir. In a hamster model of COVID-19, the combination of Nirmatrelvir with HA15 alleviated pneumonia-induced pulmonary atelectasis more effectively than the single drugs. In conclusion, inhibition of the virus Main protease and cellular GRP78 cooperatively diminishes virus replication and may improve COVID-19 therapy.

8 September 2025
Verified
Dataset
Closed access
KKKsenia Krooß
Ksenia Krooß
ARAnne Rademacher
Anne Rademacher
AHAlik Huseynov
Alik Huseynov
MBMichele Bortolomeazzi
Michele Bortolomeazzi
SWSina Jasmin Wille
Sina Jasmin Wille
KSKerstin Schipper
Kerstin Schipper
BioStudies – one package for all the data supporting a study

16 July 2026 in Nature Communications
Verified
Journal Article
Open access
SPSophia J Pribus
Sophia J Pribus
IOIvana Osredek
Ivana Osredek
JOJan Otoničar
Jan Otoničar
MSMilena Simovic-Lorenz
Milena Simovic-Lorenz
CGChiara Giovenino
Chiara Giovenino
AEAurélie Ernst
Aurélie Ernst
Bladder cancer is frequent and highly recurrent. Despite recent advances, knowledge gaps remain in molecular mechanisms underlying disease progression. In this study, we apply integrated multi-omic analyses to a cohort of 48 bladder cancer patients to comprehensively profile genetic, epigenetic, transcriptomic, and spatial features. Combining cell-free DNA sequencing, long-read tumor DNA-sequencing, RNA-sequencing, and spatial transcriptomics, we explore molecular alterations driving bladder cancer. We find frequent somatic LINE-1 (L1) insertions, and show that these L1 insertions are active and occur early in bladder cancer development. We link somatic L1 insertion with downstream genomic rearrangements and chromosomal instability, including increased structural variant and extrachromosomal DNA (ecDNA) counts in patients with high L1 counts. We identify variable ecDNA enrichment across tissue architecture, with highest enrichment overlapping differential expression of APOBEC3B and immune response pathways. In summary, our results support a model whereby L1 retrotransposition triggers downstream genomic instability and viral mimicry response.